We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+16.12%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.94B
AUM Growth
+$295M
Cap. Flow
+$29.2M
Cap. Flow %
0.74%
Top 10 Hldgs %
26.69%
Holding
163
New
20
Increased
50
Reduced
30
Closed
15

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$44.7M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$22.4M
3
INZY
Inozyme Pharma
INZY
+$21.9M
4
KYMR icon
Kymera Therapeutics
KYMR
+$21.7M
5
HUM icon
Humana
HUM
+$20.7M

Top Sells

Rank Stock Value
1
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$41.5M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$32M
3
CI icon
Cigna
CI
+$30.2M
4
AMGN icon
Amgen
AMGN
+$29.7M
5
ALLO icon
Allogene Therapeutics
ALLO
+$18.9M

Sector Composition

Rank Sector Weight
1 Healthcare 90.05%
2 Consumer Staples 1.43%
3 Consumer Discretionary 0.93%
4 Industrials 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TXG icon
101
10x Genomics
TXG
$7.65B
$9.48M 0.24%
76,000
– –
RDUS
102
DELISTED
Radius Health, Inc.
RDUS
$9.23M 0.23%
814,208
-189,051
-19% -$2.34M
CHMA
103
DELISTED
Chiasma, Inc. Common Stock
CHMA
$9.22M 0.23%
2,144,225
+751,913
+54% +$3.6M
PRTK
104
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$9.05M 0.23%
1,673,414
+18,250
+1% +$90.4K
NRIX icon
105
Nurix Therapeutics
NRIX
$2.69B
$8.99M 0.23%
+257,514
New +$6.49M
TBIO
106
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$8.75M 0.22%
642,646
-18,622
-3% -$287K
GMDA
107
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$8.37M 0.21%
2,016,656
– –
JAZZ icon
108
Jazz Pharmaceuticals
JAZZ
$16.2B
$8.2M 0.21%
+57,500
New +$7.13M
XENT
109
DELISTED
Intersect ENT, Inc
XENT
$8.15M 0.21%
500,000
– –
WST icon
110
West Pharmaceutical
WST
$24.6B
$7.83M 0.2%
28,500
-42,500
-60% -$11.2M
LEGN icon
111
Legend Biotech
LEGN
$4.22B
$7.78M 0.2%
252,138
+46,242
+22% +$1.56M
ZGNX
112
DELISTED
Zogenix, Inc.
ZGNX
$7.46M 0.19%
415,982
– –
ELVN icon
113
Enliven Therapeutics
ELVN
$4.26B
$7.3M 0.19%
89,736
-1,447
-2% -$131K
MYOV
114
DELISTED
Myovant Sciences Ltd.
MYOV
$7.2M 0.18%
512,711
+4,300
+0.8% +$80K
ANNX icon
115
Annexon
ANNX
$873M
$7.16M 0.18%
+236,811
New +$5.56M
DVAX
116
DELISTED
Dynavax Technologies
DVAX
$7.12M 0.18%
1,647,920
-12,200
-0.7% -$87K
MGNX icon
117
MacroGenics
MGNX
$257M
$6.62M 0.17%
262,641
+28,125
+12% +$768K
ODT
118
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$6.57M 0.17%
489,432
+52,201
+12% +$1.48M
BCEL
119
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$6.3M 0.16%
+450,830
New +$6.72M
NGM
120
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$5.74M 0.15%
360,454
+3,045
+0.9% +$55.5K
XENE icon
121
Xenon Pharmaceuticals
XENE
$6.2B
$5.71M 0.14%
515,711
– –
ITOS
122
DELISTED
iTeos Therapeutics
ITOS
$5.59M 0.14%
+226,681
New +$6.1M
GDRX icon
123
GoodRx Holdings
GDRX
$1.28B
$5.56M 0.14%
+100,000
New +$5.29M
TLPH icon
124
Talphera
TLPH
$73.7M
$5.36M 0.14%
+188,679
New +$4.68M
ACRS icon
125
Aclaris Therapeutics
ACRS
$866M
$5.34M 0.14%
2,076,307
+432,292
+26% +$967K
3 4
5
6 7

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, Rock Springs Capital Management held 163 positions worth $3.94B, up 8.1% from $3.65B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rock Springs Capital Management's Q3 2020 filing shows 20 new, 50 increased, 30 reduced and 15 closed positions. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 650,000 shares worth $50.5M. The largest sale was Portola Pharmaceuticals, Inc., an estimated $41.5M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 92% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

  • Rock Springs Capital Management's largest Q3 2020 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 650,000 shares worth $50.5M.
  • Rock Springs Capital Management added most to Acadia Pharmaceuticals in Q3 2020, an estimated $22.4M increase.
  • Rock Springs Capital Management's biggest Q3 2020 reduction was Vertex Pharmaceuticals, cutting an estimated $32M.
  • Rock Springs Capital Management fully exited Portola Pharmaceuticals, Inc. in Q3 2020, selling an estimated $41.5M.
  • Rock Springs Capital Management's ten largest holdings make up 27% of its $3.94B portfolio in Q3 2020.
  • Rock Springs Capital Management opened 20 new positions and closed 15 in Q3 2020.
  • Rock Springs Capital Management's portfolio value rose 8.1% quarter-over-quarter to $3.94B.

Based on Rock Springs Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.